Compare BWEN & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWEN | NXTC |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.0M | 44.6M |
| IPO Year | 2009 | 2019 |
| Metric | BWEN | NXTC |
|---|---|---|
| Price | $2.53 | $12.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 243.5K | 23.6K |
| Earning Date | 05-11-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.56 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $146,785,000.00 | $22,378,000.00 |
| Revenue This Year | $11.75 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.17 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.41 | $0.23 |
| 52 Week High | $4.15 | $15.74 |
| Indicator | BWEN | NXTC |
|---|---|---|
| Relative Strength Index (RSI) | 44.13 | 53.88 |
| Support Level | $1.87 | $10.77 |
| Resistance Level | $2.78 | $13.47 |
| Average True Range (ATR) | 0.14 | 1.12 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 57.32 | 60.57 |
Broadwind Inc is a precision manufacturer of structures, equipment and components for clean technology and other specialized applications. The company provide technologically high value products to customers with complex systems and stringent quality standards that operate in energy, mining and infrastructure sectors, in the United States of America. It capabilities include heavy fabrications, welding, metal rolling, coatings, gear cutting and shaping, gearbox manufacturing and repair, heat treat, assembly, engineering and packaging solutions. It operates through four operating segments namely Heavy Fabrications, Gearing, Industrial Solutions and Corporate.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.